Galecto to Participate at Jefferies Healthcare Conference
Galecto, Inc. (NASDAQ: GLTO) announced its participation at the Jefferies Healthcare Conference, scheduled for June 8-10, 2022, in New York City. The presentation will occur at 3:00 PM ET, and a live webcast will be available on Galecto's investor website. The company is dedicated to developing treatments for cancer and fibrosis, with ongoing clinical trials including GB0139 for idiopathic pulmonary fibrosis and GB2064 for myelofibrosis. For further details, visit their website.
- None.
- None.
BOSTON, May 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that management will be participating at the upcoming Jefferies Healthcare Conference, taking place on June 8-10 in New York City. Details for the event are as follows:
| Jefferies Healthcare Conference | |
| Date: | June 8, 2022 |
| Time: | 3:00 pm ET |
| Webcast: | Click HERE |
A live webcast of the presentation will be available on the “News & Events” section of Galecto’s Investor website at https://ir.galecto.com/news-and-events/events. A replay of the presentation will be available on this same website following the event.
About Galecto
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 (and the galectin family generally) and LOXL2. Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2a trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a Phase 1b/2a trial in liver cirrhosis and (iv) an orally active galectin-3 inhibitor (GB1211) in a separate planned phase 2 trial for the treatment of NSCLC in combination with atezolizumab (Tecentriq®).
Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.
For more information, contact:
| Galecto, Inc. | |
| Hans Schambye, CEO Jon Freve, CFO | |
| +45 70 70 52 10 | |
Investor Relations US | Investor/Media Relations EU |
| Ashley R. Robinson arr@lifesciadvisors.com | Sandya von der Weid svonderweid@lifesciadvisors.com |
| +1 617 430 7577 | +41 78 680 0538 |
FAQ
What is the date of the Jefferies Healthcare Conference for Galecto (GLTO)?
What time will Galecto present at the Jefferies Healthcare Conference?
How can I watch Galecto's presentation at the Jefferies Healthcare Conference?
What are Galecto's current clinical trials focused on?
Where can I find more information about Galecto (GLTO)?
